AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2338632 — intervention group
Group type: EXPERIMENTAL
Intervention: SR-verapamil with food (1 X 240 mg)
Number of subjects: 12
Study 2338632 — intervention group
Group type: COMPARATOR
Intervention: Conventional formulation of verapamil fasting (3 X 80 mg)
Number of subjects: 12
Study 7448345 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinidine formulation 1
Number of subjects: 12
Study 7448345 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinidine formulation 2
Number of subjects: 12
Study 7448345 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinidine formulation 3
Number of subjects: 12
Study 30423463 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids (15 x 300 mg capsules per day for 12 weeks)
Number of subjects: 0
Study 30423463 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study 30423463 — intervention group
Group type: COMPARATOR
Intervention: Comparison between Omega-3 and Placebo
Number of subjects: 0
Study 29127432 — intervention group
Group type: EXPERIMENTAL
Intervention: DSAEK with donor cornea preservation time (PT) of 0 to 7 days (0-7d PT)
Number of subjects: 769
Study 29127432 — intervention group
Group type: COMPARATOR
Intervention: DSAEK with donor cornea preservation time (PT) of 8 to 14 days (8-14d PT)
Number of subjects: 769
Study 29127432 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer PT analyzed as a continuous variable
Number of subjects: 769
Study 29127432 — intervention group
Group type: EXPERIMENTAL
Intervention: Extension study results at 4 years for 0-7d PT
Number of subjects: 769
Study 29127432 — intervention group
Group type: COMPARATOR
Intervention: Extension study results at 4 years for 8-14d PT
Number of subjects: 769
Study 26468632 — intervention group
Group type: EXPERIMENTAL
Intervention: Earlier appointment to outpatient cardiac rehabilitation (CR) at HFH (8 days)
Number of subjects: 148
Study 26468632 — intervention group
Group type: COMPARATOR
Intervention: Standard routine appointment to outpatient cardiac rehabilitation (CR) at Mayo Clinic (10 days after discharge)
Number of subjects: 148
Study 23493643 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate (234 mg on day 1, 156 mg on day 8, then once-monthly flexible dosing)
Number of subjects: 747
Study 23493643 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone long-acting injectable (RLAI) (25-50 mg biweekly, with oral risperidone supplementation on days 1-28)
Number of subjects: 747
Study 21627523 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy (ESWT)
Number of subjects: 24
Study 21627523 — intervention group
Group type: EXPERIMENTAL
Intervention: Polysulfated glycosaminoglycan treatment (PSGAGT)
Number of subjects: 24
Study 21627523 — intervention group
Group type: COMPARATOR
Intervention: Sham ESWT (placebo)
Number of subjects: 24
Study 19862981 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin with target INR of 1.50 to 1.99 (Group A)
Number of subjects: 180
Study 19862981 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin with target INR of 2.00 to 2.50 (Group B)
Number of subjects: 180
Study 19862981 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin with target INR of 2.51 to 3.00 (Group C)
Number of subjects: 180
Study 19862981 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin with target INR of 1.50 to 2.50 (Group A and B)
Number of subjects: 180
Study 16681849 — intervention group
Group type: COMPARATOR
Intervention: Lesbian women
Number of subjects: 1605
Study 16681849 — intervention group
Group type: COMPARATOR
Intervention: Bisexual women
Number of subjects: 1605
Study 16681849 — intervention group
Group type: COMPARATOR
Intervention: Gay men
Number of subjects: 1605
Study 16681849 — intervention group
Group type: COMPARATOR
Intervention: Bisexual men
Number of subjects: 1605
Study 16681849 — intervention group
Group type: COMPARATOR
Intervention: Lesbian, gay, and bisexual classified people
Number of subjects: 1605
Study 15169803 — intervention group
Group type: EXPERIMENTAL
Intervention: TAP (doxorubicin 45 mg/m(2), cisplatin 50 mg/m(2), paclitaxel 160 mg/m(2) with filgrastim)
Number of subjects: 273
Study 15169803 — intervention group
Group type: COMPARATOR
Intervention: AP (doxorubicin 60 mg/m(2), cisplatin 50 mg/m(2))
Number of subjects: 273
Study 15169803 — intervention group
Group type: EXPERIMENTAL
Intervention: TAP
Number of subjects: 273
Study 15169803 — intervention group
Group type: COMPARATOR
Intervention: AP
Number of subjects: 273
Study 11419831 — intervention group
Group type: EXPERIMENTAL
Intervention: Covered stents
Number of subjects: 62
Study 11419831 — intervention group
Group type: COMPARATOR
Intervention: Uncovered stents
Number of subjects: 62
Study 9426847 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril
Number of subjects: 0
Study 9426847 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8489566 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate release bezafibrate 300 mg dragee (A)
Number of subjects: 0
Study 8489566 — intervention group
Group type: COMPARATOR
Intervention: Sustained release bezafibrate 400 mg dragee (B)
Number of subjects: 0
Study 3318368 — intervention group
Group type: EXPERIMENTAL
Intervention: Mexiletine (200 to 400 mg every 8 hours)
Number of subjects: 491
Study 3318368 — intervention group
Group type: COMPARATOR
Intervention: Quinidine (200 to 400 mg every 6 hours)
Number of subjects: 491
Study 3318368 — intervention group
Group type: COMPARATOR
Intervention: Quinidine
Number of subjects: 491
Study 3318368 — intervention group
Group type: EXPERIMENTAL
Intervention: Mexiletine
Number of subjects: 491
Study 3318368 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 491
Study 28426897 — intervention group
Group type: EXPERIMENTAL
Intervention: Aware condition
Number of subjects: 82
Study 28426897 — intervention group
Group type: EXPERIMENTAL
Intervention: Count duration of 15 seconds
Number of subjects: 82
Study 28426897 — intervention group
Group type: EXPERIMENTAL
Intervention: Count duration of 30 seconds
Number of subjects: 82
Study 28426897 — intervention group
Group type: COMPARATOR
Intervention: Unaware condition
Number of subjects: 82
Study 27162173 — intervention group
Group type: COMPARATOR
Intervention: ASP015K (peficitinib) 3 mg to 300 mg single dose
Number of subjects: 20
Study 27162173 — intervention group
Group type: COMPARATOR
Intervention: ASP015K (30 mg) multiple doses
Number of subjects: 20
Study 27162173 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 24998109 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinogen concentrate (1g administered 30 min prior to operation)
Number of subjects: 60
Study 24998109 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 60
Study 24998109 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinogen concentrate
Number of subjects: 60
Study 22649162 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Sensory Motor Training Therapy (Perfetti's method)
Number of subjects: 40
Study 22649162 — intervention group
Group type: COMPARATOR
Intervention: Conventional occupational therapy
Number of subjects: 40
Study 20854237 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic asthma care involving a register-recall system, postcard prompts for review, and education for general practitioners and staff.
Number of subjects: 565
Study 20854237 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care).
Number of subjects: 565
Study 19029500 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-care programs (telephone and face-to-face)
Number of subjects: 234
Study 19029500 — intervention group
Group type: COMPARATOR
Intervention: Education control group (26 biweekly newsletters)
Number of subjects: 234
Study 16125761 — intervention group
Group type: EXPERIMENTAL
Intervention: Outreach and counseling intervention
Number of subjects: 348
Study 16125761 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 348
Study 12098612 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain communication intervention
Number of subjects: 145
Study 12098612 — intervention group
Group type: EXPERIMENTAL
Intervention: PTSD diagnosis (53.8% of participants)
Number of subjects: 145
Study 10189646 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine with 1:100,000 epinephrine buffered 9:1 with 8.4% sodium bicarbonate
Number of subjects: 30
Study 10189646 — intervention group
Group type: COMPARATOR
Intervention: 2% lidocaine with 1:100,000 epinephrine
Number of subjects: 30
Study 10189646 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine with 1:100,000 epinephrine diluted 1:9 with 0.9% bacteriostatic saline solution
Number of subjects: 30
Study 7780131 — intervention group
Group type: EXPERIMENTAL
Intervention: rBPI23 (1 mg/kg)
Number of subjects: 8
Study 2185335 — intervention group
Group type: EXPERIMENTAL
Intervention: Recall system and patient education material by mail
Number of subjects: 178
Study 376786 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 30406937 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin K antagonists (VKAs)
Number of subjects: 3528
Study 30406937 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-vitamin K oral anticoagulants (NOACs)
Number of subjects: 3528
Study 31392719 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational programme
Number of subjects: 70
Study 31392719 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 70
Study 29472255 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional stimulus group (EG) - watched an emotionally stimulating video prior to the BLS course
Number of subjects: 271
Study 29472255 — intervention group
Group type: COMPARATOR
Intervention: Assessment group (AG) - practical assessment of the BLS algorithm announced and tested
Number of subjects: 271
Study 29472255 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (EG and AG)
Number of subjects: 271
Study 27797697 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol media literacy program (10 lessons)
Number of subjects: 165
Study 27797697 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 165
Study 27797697 — intervention group
Group type: COMPARATOR
Intervention: Both groups (intervention and control)
Number of subjects: 165
Study 27797697 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol media literacy program
Number of subjects: 165
Study 25146009 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 3% mepivacaine plus 2% lidocaine with 1:100,000 epinephrine
Number of subjects: 100
Study 25146009 — intervention group
Group type: COMPARATOR
Intervention: Combination of 2% lidocaine with 1:100,000 epinephrine plus 2% lidocaine with 1:100,000 epinephrine
Number of subjects: 100
Study 22545190 — intervention group
Group type: EXPERIMENTAL
Intervention: SURG+AMOX+MET+TET
Number of subjects: 229
Study 22545190 — intervention group
Group type: EXPERIMENTAL
Intervention: SURG
Number of subjects: 229
Study 22545190 — intervention group
Group type: COMPARATOR
Intervention: SRP alone
Number of subjects: 229
Study 22545190 — intervention group
Group type: COMPARATOR
Intervention: SURG+systemic amoxicillin+systemic metronidazole
Number of subjects: 229
Study 22545190 — intervention group
Group type: COMPARATOR
Intervention: SURG+local tetracycline
Number of subjects: 229
Study 22545190 — intervention group
Group type: COMPARATOR
Intervention: AMOX+MET+TET
Number of subjects: 229
Study 22545190 — intervention group
Group type: COMPARATOR
Intervention: AMOX+MET
Number of subjects: 229
Study 22545190 — intervention group
Group type: COMPARATOR
Intervention: TET
Number of subjects: 229
Study 20008028 — intervention group
Group type: EXPERIMENTAL
Intervention: Reasoning intervention group
Number of subjects: 1534
Study 20008028 — intervention group
Group type: EXPERIMENTAL
Intervention: Speed of processing intervention group
Number of subjects: 1534
Study 20008028 — intervention group
Group type: COMPARATOR
Intervention: Memory intervention group
Number of subjects: 1534
Study 20008028 — intervention group
Group type: COMPARATOR
Intervention: No-contact control group
Number of subjects: 1534
Study 18341676 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerochamber Plus spacer (AP)
Number of subjects: 17
Study 18341676 — intervention group
Group type: EXPERIMENTAL
Intervention: Synchro‐Breathe (SB) device
Number of subjects: 17
Study 18341676 — intervention group
Group type: COMPARATOR
Intervention: pMDI Evohaler (EH)
Number of subjects: 17
Study 15981555 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol (target dose 5 mg)
Number of subjects: 60
Study 15981555 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 12706495 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (INO) at 20 ppm
Number of subjects: 22
Study 10606909 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraportal infusion of lymphokine‐activated killer (LAK) cells combined with recombinant interleukin 2 (rIL‐2)
Number of subjects: 29
Study 10606909 — intervention group
Group type: COMPARATOR
Intervention: Control group (tumour resection and IORT)
Number of subjects: 29
Study 10606909 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment group (resection, IORT and LAK cells with rIL-2)
Number of subjects: 29
Study 10606909 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 29
Study 8847783 — intervention group
Group type: EXPERIMENTAL
Intervention: Amrinon (AM) 1 microgram.kg-1 followed by AM 5 micrograms.kg-1.min-1
Number of subjects: 39
Study 8847783 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (PG) 0.02 micrograms.kg-1.min-1
Number of subjects: 39
Study 8847783 — intervention group
Group type: COMPARATOR
Intervention: Dopamine (DOA) 3 micrograms.kg-1.min-1 (Control)
Number of subjects: 39
Study 8847783 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 39
Study 8847783 — intervention group
Group type: EXPERIMENTAL
Intervention: AM and PG groups
Number of subjects: 39
Study 1734247 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous methylprednisolone (1 g per day for 3 days, followed by oral prednisone 1 mg/kg/day for 11 days)
Number of subjects: 457
Study 1734247 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisone (1 mg/kg/day for 14 days)
Number of subjects: 457
Study 1734247 — intervention group
Group type: COMPARATOR
Intervention: Placebo (oral for 14 days)
Number of subjects: 457
Study 6432198 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin
Number of subjects: 10
Study 6432198 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31663905 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic nomogram based on age, CA19.9, and 6 radiological features.
Number of subjects: 587
Study 31663905 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram
Number of subjects: 587
Study 30245282 — intervention group
Group type: EXPERIMENTAL
Intervention: Puerarin 400mg
Number of subjects: 119
Study 30245282 — intervention group
Group type: COMPARATOR
Intervention: Control (no puerarin)
Number of subjects: 119
Study 26786575 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive therapy group (74% experienced serious hypoglycemia)
Number of subjects: 197
Study 26786575 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment group (21% experienced serious hypoglycemia)
Number of subjects: 197
Study 26786575 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment group
Number of subjects: 197
Study 26786575 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive therapy group
Number of subjects: 197
Study 25480613 — intervention group
Group type: EXPERIMENTAL
Intervention: Snare cauterization
Number of subjects: 62
Study 25480613 — intervention group
Group type: COMPARATOR
Intervention: Clip closure
Number of subjects: 62
Study 22629322 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjustment for a strong prognostic factor (PF) with relative risk = 5
Number of subjects: 125
Study 22629322 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjustment for a weak prognostic factor (PF) with relative risk = 2
Number of subjects: 125
Study 22629322 — intervention group
Group type: EXPERIMENTAL
Intervention: Including 1000 patients/arm
Number of subjects: 125
Study 22629322 — intervention group
Group type: EXPERIMENTAL
Intervention: Including 2000 patients/arm
Number of subjects: 125
Study 22629322 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression models with adjustment for PF
Number of subjects: 125
Study 22629322 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression models without adjustment for PF
Number of subjects: 125
Study 20236094 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg i.v.
Number of subjects: 113
Study 20236094 — intervention group
Group type: COMPARATOR
Intervention: Diphenhydramine 25 mg i.v.
Number of subjects: 113
Study 18519309 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal fixation with a Herbert screw
Number of subjects: 83
Study 18519309 — intervention group
Group type: COMPARATOR
Intervention: Nonoperative treatment with a cast
Number of subjects: 83
Study 16042226 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIG (1 g/kg body weight monthly for 27 months)
Number of subjects: 318
Study 16042226 — intervention group
Group type: COMPARATOR
Intervention: Placebo (albumin 0.1% monthly for 27 months)
Number of subjects: 318
Study 16042226 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIG
Number of subjects: 318
Study 16042226 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 318
Study 12457125 — intervention group
Group type: EXPERIMENTAL
Intervention: La Léchère mineral water
Number of subjects: 10
Study 12457125 — intervention group
Group type: COMPARATOR
Intervention: Distilled water
Number of subjects: 10
Study 10609979 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol intoxication
Number of subjects: 0
Study 8949805 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.6 mg kg‐1 (2xED95)
Number of subjects: 100
Study 8949805 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.9 mg kg‐1 (3xED95)
Number of subjects: 100
Study 1918655 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 120
Study 1918655 — intervention group
Group type: COMPARATOR
Intervention: Clomipramine
Number of subjects: 120
Study 6437699 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 9
Study 6437699 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 29157034 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin plus IV ibuprofen (150 mg pregabalin and 400 mg IV ibuprofen)
Number of subjects: 58
Study 29157034 — intervention group
Group type: COMPARATOR
Intervention: Pregabalin (150 mg)
Number of subjects: 58
Study 29427823 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized strategy
Number of subjects: 676
Study 29427823 — intervention group
Group type: COMPARATOR
Intervention: Open strategy
Number of subjects: 676
Study 29427823 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized strategy - first step tests
Number of subjects: 676
Study 29427823 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized strategy - second step tests
Number of subjects: 676
Study 29427823 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized group vs Open group for HLA B27 and ACE
Number of subjects: 676
Study 29427823 — intervention group
Group type: EXPERIMENTAL
Intervention: Free investigations or guided tests
Number of subjects: 676
Study 29427823 — intervention group
Group type: EXPERIMENTAL
Intervention: Third intention tests
Number of subjects: 676
Study 27213500 — intervention group
Group type: EXPERIMENTAL
Intervention: Supramaximal interval training (10 cycles of 10-second work at 140% peak aerobic power with 5-second recovery, repeated 6 times)
Number of subjects: 16
Study 27213500 — intervention group
Group type: COMPARATOR
Intervention: Continuous training (predominantly moderate intensity below lactate threshold)
Number of subjects: 16
Study 27213500 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Supramaximal and Continuous)
Number of subjects: 16
Study 24275625 — intervention group
Group type: EXPERIMENTAL
Intervention: Split toric lenses misaligned by 0°, 5° or 10°
Number of subjects: 2
Study 24275625 — intervention group
Group type: EXPERIMENTAL
Intervention: Split toric lenses misaligned around 180°
Number of subjects: 2
Study 24275625 — intervention group
Group type: EXPERIMENTAL
Intervention: Split toric power misaligned with low cylinder
Number of subjects: 2
Study 24275625 — intervention group
Group type: EXPERIMENTAL
Intervention: Split toric power misaligned with high cylinder
Number of subjects: 2
Study 24275625 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted astigmats with split toric power misaligned
Number of subjects: 2
Study 19465507 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirror therapy
Number of subjects: 48
Study 19465507 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 48
Study 15182276 — intervention group
Group type: EXPERIMENTAL
Intervention: BUD + M group (400 microg/day of inhaled budesonide plus 10 mg/day of montelukast)
Number of subjects: 30
Study 15182276 — intervention group
Group type: COMPARATOR
Intervention: High BUD group (800 microg/day of inhaled budesonide)
Number of subjects: 30
Study 11263112 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training (n = 19)
Number of subjects: 44
Study 11263112 — intervention group
Group type: COMPARATOR
Intervention: Active control (group walk session, n = 25)
Number of subjects: 44
Study 9239584 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (0.5 mg/kg)
Number of subjects: 0
Study 9239584 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomidate (0.1 mg/kg)
Number of subjects: 0
Study 9239584 — intervention group
Group type: COMPARATOR
Intervention: Sufentanil/N2O anesthesia
Number of subjects: 0
Study 8107484 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (on a bicycle ergometer or treadmill) to self-imposed maximum
Number of subjects: 10
Study 8107484 — intervention group
Group type: COMPARATOR
Intervention: Quiet rest in a soundproof chamber
Number of subjects: 10
Study 3302251 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplement (multivitamin/multimineral) at high and low dosage
Number of subjects: 11
Study 3302251 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11